|
1
|
Hartke J, Johnson M and Ghabril M: The
diagnosis and treatment of hepatocellular carcinoma. Semin Diagn
Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Costentin C: Hepatocellular carcinoma
surveillance. Presse Med. 46:381–385. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang JF, Lao YC, Yuan BH, Yin J, Liu X,
Chen L and Zhong JH: Treatment of hepatocellular carcinoma with
portal vein tumor thrombus: Advances and challenges. Oncotarget.
8:33911–33921. 2017.PubMed/NCBI
|
|
4
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsueh KC, Lee TY, Kor CT, Chen TM, Chang
TM, Yang SF and Hsieh CB: The role of liver transplantation or
resection for patients with early hepatocellular carcinoma. Tumour
Biol. 37:4193–4201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hollebecque A, Malka D, Ferte C, Ducreux M
and Boige V: Systemic treatment of advanced hepatocellular
carcinoma: From disillusions to new horizons. Eur J Cancer.
51:327–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi XS, Guo XZ, Han GH, Li HY and Chen J:
MET inhibitors for treatment of advanced hepatocellular carcinoma:
A review. World J Gastroenterol. 21:5445–5453. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdel-Rahman O and Fouad M:
Sorafenib-based combination as a first line treatment for advanced
hepatocellular carcinoma: A systematic review of the literature.
Crit Rev Oncol Hematol. 91:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu BN, Yan HQ, Wu X, Pan ZH, Zhu Y, Meng
ZW, Zhou QH and Xu K: Apoptosis induced by benzyl isothiocyanate in
gefitinib-resistant lung cancer cells is associated with Akt/MAPK
pathways and generation of reactive oxygen species. Cell Biochem
Biophys. 66:81–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao ZQ, Yu ZY, Li J and Ouyang XN:
Gefitinib induces lung cancer cell autophagy and apoptosis via
blockade of the PI3K/AKT/mTOR pathway. Oncol Lett. 12:63–68. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu PH, Kuo TC, Chang KC, Chang CH and Chu
CY: Gefitinib-induced epidermal growth factor receptor-independent
keratinocyte apoptosis is mediated by the JNK activation pathway.
Br J Dermatol. 164:38–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schiffer E, Housset C, Cacheux W, Wendum
D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V and
Rosmorduc O: Gefitinib, an EGFR inhibitor, prevents hepatocellular
carcinoma development in the rat liver with cirrhosis. Hepatology.
41:307–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Akiyama T, Ishida J, Nakagawa S, Ogawara
H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a
specific inhibitor of tyrosine-specific protein kinases. J Biol
Chem. 262:5592–5595. 1987.PubMed/NCBI
|
|
15
|
Banerjee S, Li Y, Wang Z and Sarkar FH:
Multi-targeted therapy of cancer by genistein. Cancer Lett.
269:226–242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li S, Li J, Dai W, Zhang Q, Feng J, Wu L,
Liu T, Yu Q, Xu S, Wang W, et al: Genistein suppresses aerobic
glycolysis and induces hepatocellular carcinoma cell death. Br J
Cancer. 117:1518–1528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gruca A, Krawczyk Z, Szeja W, Grynkiewicz
G and Rusin A: Synthetic genistein glycosides inhibiting EGFR
phosphorylation enhance the effect of radiation in HCT 116 colon
cancer cells. Molecules. 19:18558–18573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu JF, Ji J, Dong SY, Li BB, Yu ML, Wu DD,
Tao L and Tong XH: Gefitinib enhances oxaliplatin-induced apoptosis
mediated by Src and PKC-modulated gap junction function. Oncol Rep.
36:3251–3258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kishida O, Miyazaki Y, Murayama Y, Ogasa
M, Miyazaki T, Yamamoto T, Watabe K, Tsutsui S, Kiyohara T,
Shimomura I and Shinomura Y: Gefitinib (‘Iressa’, ZD1839) inhibits
SN38-triggered EGF signals and IL-8 production in gastric cancer
cells. Cancer Chemother Pharmacol. 55:584–594. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang T, Gu J, Liu T, Ma H, Ma X, Tao J,
Jin Y and Liang X: Expression of acetaldehyde dehydrogenase in
gefitinib-resistant human lung adenocarcinoma HCC-827/GR cells.
Zhongguo Fei Ai Za Zhi. 21:431–436. 2018.(In Chinese). PubMed/NCBI
|
|
23
|
Nakashima S, Koike T and Nozawa Y:
Genistein, a protein tyrosine kinase inhibitor, inhibits
thromboxane A2-mediated human platelet responses. Mol Pharmacol.
39:475–480. 1991.PubMed/NCBI
|
|
24
|
Papazisis KT, Zambouli D, Kimoundri OT,
Papadakis ES, Vala V, Geromichalos GD, Voyatzi S, Markala D,
Destouni E, Boutis L and Kortsaris AH: Protein tyrosine kinase
inhibitor, genistein, enhances apoptosis and cell cycle arrest in
K562 cells treated with gamma-irradiation. Cancer Lett.
160:107–113. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Duursen MB, Nijmeijer SM, de Morree
ES, de Jong PC and van den Berg M: Genistein induces breast
cancer-associated aromatase and stimulates estrogen-dependent tumor
cell growth in in vitro breast cancer model. Toxicology. 289:67–73.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Geller J, Sionit L, Partido C, Li L, Tan
X, Youngkin T, Nachtsheim D and Hoffman RM: Genistein inhibits the
growth of human-patient BPH and prostate cancer in histoculture.
Prostate. 34:75–79. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tian T, Li J, Li B, Wang Y, Li M, Ma D and
Wang X: Genistein exhibits anti-cancer effects via down-regulating
FoxM1 in H446 small-cell lung cancer cells. Tumour Biol.
35:4137–4145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han C, Michalopoulos GK and Wu T:
Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor
tyrosine kinases and enhances invasiveness in human hepatocellular
carcinoma cells. J Cell Physiol. 207:261–270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang W, Ma XP, Shi Z, Zhang P, Ding DL,
Huang HX, Saiyin HG, Chen TY, Lu PX, Wang NJ, et al: Epidermal
growth factor receptor pathway polymorphisms and the prognosis of
hepatocellular carcinoma. Am J Cancer Res. 5:396–410.
2014.PubMed/NCBI
|
|
30
|
Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang
H, Yang X, Wan X, Lu X, Sang X and Zhao H: Combination treatment
including targeted therapy for advanced hepatocellular carcinoma.
Oncotarget. 7:71036–71051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF
and De Luo B: Synergistic inhibitory effects by the combination of
gefitinib and genistein on NSCLC with acquired drug-resistance in
vitro and in vivo. Mol Biol Rep. 39:4971–4979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boulares AH, Yakovlev AG, Ivanova V,
Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose)
polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP
mutant increases rates of apoptosis in transfected cells. J Biol
Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo H, Liang H, Chen J, Xu Y, Chen Y, Xu
L, Yun L, Liu J, Yang H, Liu L, et al: Hydroquinone induces TK6
cell growth arrest and apoptosis through PARP-1/p53 regulatory
pathway. Environ Toxicol. 32:2163–2171. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu J, Zhang X, Wang H, Ge S, Gao T, Song
L, Wang X, Li H, Qin Y and Zhang Z: HCRP1 downregulation promotes
hepatocellular carcinoma cell migration and invasion through the
induction of EGFR activation and epithelial-mesenchymal transition.
Biomed Pharmacother. 88:421–429. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lv X, Fang C, Yin R, Qiao B, Shang R, Wang
J, Song W, He Y and Chen Y: Agrin para-secreted by PDGF-activated
human hepatic stellate cells promotes hepatocarcinogenesis in vitro
and in vivo. Oncotarget. 8:105340–105355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang
X, Wang Z, Yang Y, Chen C, Wang Z and Wu Q: The
PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal
transition in gemcitabine resistance hepatoma cells. Oncotarget.
6:7000–7010. 2015.PubMed/NCBI
|
|
37
|
Ni J, Zhou LL, Ding L, Zhao X, Cao H, Fan
F, Li H, Lou R, Du Y, Dong S, et al: PPARγ agonist efatutazone and
gefitinib synergistically inhibit the proliferation of
EGFR-TKI-resistant lung adenocarcinoma cells via the
PPARgamma/PTEN/Akt pathway. Exp Cell Res. 361:246–256. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakamura H and Wang Y, Kurita T, Adomat H,
Cunha GR and Wang Y: Genistein increases epidermal growth factor
receptor signaling and promotes tumor progression in advanced human
prostate cancer. PLoS One. 6:e200342011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Little PJ, Getachew R, Rezaei HB,
Sanchez-Guerrero E, Khachigian LM, Wang H, Liao S, Zheng W,
Ballinger ML and Osman N: Genistein inhibits PDGF-stimulated
proteoglycan synthesis in vascular smooth muscle without blocking
PDGFβ receptor phosphorylation. Arch Biochem Biophys. 525:25–31.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ono M and Kuwano M: Molecular mechanisms
of epidermal growth factor receptor (EGFR) activation and response
to gefitinib and other EGFR-targeting drugs. Clin Cancer Res.
12:7242–7251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tanjak P, Thiantanawat A, Watcharasit P
and Satayavivad J: Genistein reduces the activation of AKT and
EGFR, and the production of IL6 in cholangiocarcinoma cells
involving estrogen and estrogen receptors. Int J Oncol. 53:177–188.
2018.PubMed/NCBI
|
|
42
|
Bodine SC, Stitt TN, Gonzalez M, Kline WO,
Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC,
Glass DJ and Yancopoulos GD: Akt/mTOR pathway is a crucial
regulator of skeletal muscle hypertrophy and can prevent muscle
atrophy in vivo. Nat Cell Biol. 3:1014–1019. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Missiaglia E, Dalai I, Barbi S, Beghelli
S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A,
delle Fave G, et al: Pancreatic endocrine tumors: Expression
profiling evidences a role for AKT-mTOR pathway. J Clin Oncol.
28:245–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sahin K, Tuzcu M, Basak N, Caglayan B,
Kilic U, Sahin F and Kucuk O: Sensitization of cervical cancer
cells to cisplatin by genistein: The role of NFκB and Akt/mTOR
signaling pathways. J Oncol. 2012:4615622012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Block M, Gründker C, Fister S, Kubin J,
Wilkens L, Mueller MD, Hemmerlein B, Emons G and Günthert AR:
Inhibition of the AKT/mTOR and erbB pathways by gefitinib,
perifosine and analogs of gonadotropin-releasing hormone I and II
to overcome tamoxifen resistance in breast cancer cells. Int J
Oncol. 41:1845–1854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li W, Tan D, Zhang Z, Liang JJ and Brown
RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in
hepatocellular carcinoma. Oncol Rep. 20:713–719. 2008.PubMed/NCBI
|
